Compare Stocks → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BSTCNASDAQ:LXRXNASDAQ:PRVBNASDAQ:REPH Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBSTCBioSpecifics Technologies$88.53$88.47$42.00▼$89.15$650.25M0.2461,105 shsN/ALXRXLexicon Pharmaceuticals$1.57+2.0%$2.24$0.92▼$3.79$386.75M1.274.33 million shs659,872 shsPRVBProvention Bio$24.98+3.1%$24.58$3.18▼$25.00$2.37B2.472.28 million shs9.12 million shsREPHRecro Pharma$1.73$1.38▼$3.79$117.93M1.08126,298 shs141,800 shs7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBSTCBioSpecifics Technologies0.00%0.00%0.00%0.00%0.00%LXRXLexicon Pharmaceuticals-3.75%-5.52%-22.22%-15.38%-36.10%PRVBProvention Bio0.00%0.00%0.00%0.00%0.00%REPHRecro Pharma0.00%0.00%0.00%0.00%0.00%Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (Ad)The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBSTCBioSpecifics TechnologiesN/AN/AN/AN/AN/AN/AN/AN/ALXRXLexicon Pharmaceuticals1.6285 of 5 stars3.03.00.00.01.71.70.6PRVBProvention BioN/AN/AN/AN/AN/AN/AN/AN/AREPHRecro PharmaN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBSTCBioSpecifics TechnologiesN/AN/AN/AN/ALXRXLexicon Pharmaceuticals2.00Hold$5.00218.35% UpsidePRVBProvention BioN/AN/AN/AN/AREPHRecro PharmaN/AN/AN/AN/ACurrent Analyst RatingsLatest PRVB, BSTC, LXRX, and REPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/23/2024LXRXLexicon PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold4/11/2024LXRXLexicon PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBSTCBioSpecifics Technologies$38.19M17.03$3.38 per share26.18$18.42 per share4.81LXRXLexicon Pharmaceuticals$1.20M322.29N/AN/A$0.38 per share4.13PRVBProvention Bio$12.90M183.54N/AN/A$1.40 per share17.84REPHRecro Pharma$75.36M0.00N/AN/A$0.90 per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBSTCBioSpecifics Technologies$24.47M$3.3337.5117.60N/A47.43%14.81%14.46%N/ALXRXLexicon Pharmaceuticals-$177.12M-$0.80N/AN/AN/A-14,573.20%-138.54%-71.29%5/7/2024 (Estimated)PRVBProvention Bio-$113.57M-$1.53N/AN/AN/A-880.69%-103.36%-69.08%N/AREPHRecro Pharma-$11.37M-$0.31N/AN/AN/A-15.15%-56.66%-11.14%N/ALatest PRVB, BSTC, LXRX, and REPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/11/2024Q4 2023LXRXLexicon Pharmaceuticals-$0.23-$0.20+$0.03-$0.20$0.68 million$0.70 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBSTCBioSpecifics TechnologiesN/AN/AN/AN/AN/ALXRXLexicon PharmaceuticalsN/AN/AN/AN/AN/APRVBProvention BioN/AN/AN/AN/AN/AREPHRecro PharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBSTCBioSpecifics TechnologiesN/A66.2466.24LXRXLexicon Pharmaceuticals1.075.605.58PRVBProvention Bio0.191.931.92REPHRecro Pharma2.273.242.74OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBSTCBioSpecifics Technologies60.34%LXRXLexicon Pharmaceuticals74.70%PRVBProvention Bio37.39%REPHRecro Pharma62.34%Insider OwnershipCompanyInsider OwnershipBSTCBioSpecifics Technologies15.70%LXRXLexicon Pharmaceuticals6.80%PRVBProvention Bio13.10%REPHRecro Pharma14.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBSTCBioSpecifics Technologies77.35 millionN/ANot OptionableLXRXLexicon Pharmaceuticals285246.24 million229.49 millionOptionablePRVBProvention Bio8294.78 million82.37 millionNot OptionableREPHRecro Pharma18556.42 million48.41 millionOptionablePRVB, BSTC, LXRX, and REPH HeadlinesSourceHeadlineDorf Ketal's Indian unit acquires veterinary pharma brandvccircle.com - April 10 at 10:57 PMFuji Pharma Co. Ltd.wsj.com - January 30 at 3:34 PMAurobindo Pharma Q2 results: Net profit jumps 85% to Rs 757 croremoneycontrol.com - November 22 at 10:47 PMRetaining the human element of AI within pharma and healthcarepharmaphorum.com - November 21 at 10:06 AMHere's what Wall Street expects from Recro Pharma's earnings reportmarkets.businessinsider.com - November 7 at 12:00 PMUS supreme court halts Purdue Pharma deal that shields Sacklers from lawsuitstheguardian.com - August 16 at 1:59 AMMankind Pharma share pricelivemint.com - August 9 at 12:30 PMWhat Wall Street expects from Recro Pharma's earningsmarkets.businessinsider.com - August 9 at 7:25 AMMankind Pharma Ltd (MNKI)investing.com - August 3 at 9:00 AMEversana and Amazon plan generative AI push in pharmapharmaphorum.com - July 30 at 11:21 PMAurobindo Pharma Ltd.ndtv.com - July 25 at 12:39 AMBaudax Bio acquires Maryland biotechnology firm TeraImmune; stock jumpsbizjournals.com - June 30 at 12:44 PMPharma reform: Patients can’t afford to wait. Act now.politico.eu - June 13 at 3:41 PMSun Pharma reports "information security incident"; isolates impacted IT assetshealth.economictimes.indiatimes.com - March 9 at 7:26 AMWatch: Woody Harrelson Torches Big Pharma During Hilarious Opening Monologue on SNLijr.com - March 2 at 12:30 AMAurobindo Pharma shares gain even as Q3 profit sinks; board declares 300% dividendmoneycontrol.com - February 17 at 8:43 PMPaytm, Adani Enterprises, HUL, Sun Pharma, Lupin, Cummins, GAIL, Macrotech Developers stocks in focusfinancialexpress.com - December 20 at 8:48 AMPomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Recro Pharma, Inc. Common Stock – SCTLbenzinga.com - June 24 at 9:08 AMSocietal CDMO Increuters.com - April 20 at 9:24 AMRecro Pharma, Inc.: Recro Announces Name Change to Societal CDMO to Reflect Corporate Expansion and Transformationfinanznachrichten.de - March 22 at 10:51 PMRecro Pharma Rebrands to Societal CDMO Inc.contractpharma.com - March 22 at 5:51 PMIs Recro Pharma (REPH) a Worthy Investment?finance.yahoo.com - March 22 at 8:32 AMRecap: Recro Pharma Q4 Earningsbenzinga.com - March 1 at 11:55 PMRecro Pharma Progresses Addition of Fill/Finish, Lyophilization Capabilitiescontractpharma.com - February 23 at 9:51 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBioSpecifics TechnologiesNASDAQ:BSTCBioSpecifics Technologies Corp., a biopharmaceutical company, develops an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX and Xiapex brands. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis, human lipoma, and uterine fibroids. The company has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Wilmington, Delaware.Lexicon PharmaceuticalsNASDAQ:LXRXLexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.Provention BioNASDAQ:PRVBProvention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn's disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ.Recro PharmaNASDAQ:REPHRecro Pharma, Inc. is a pharmaceutical company, which engages in the contract development and manufacturing organization (CDMO). The firm offers integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products. The company was founded by Geraldine A. Henwood and Thomas F. Henwood on November 15, 2007 and is headquartered in Exton, PA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.